{
    "root": "e6ff9fd8-1c01-4c15-83be-aea33765b026",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Purified Cortrophin Gel",
    "value": "20250305",
    "ingredients": [
        {
            "name": "CORTICOTROPIN",
            "code": "K0U68Q2TXA",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3892"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "PHENOL",
            "code": "339NCG44TV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15882"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "purified cortrophin gel indicated following disorders : 1. rheumatic disorders : adjunctive therapy short-term ( tide patient acute episode exacerbation ) : psoriatic arthritis . rheumatoid arthritis , including juvenile rheumatoid arthritis ( selected cases may require low-dose maintenance therapy ) . ankylosing spondylitis.acute gouty arthritis . 2. collagen diseases : exacerbation maintenance therapy selected cases : systemic lupus erythematosus . systemic dermatomyositis ( polymyositis ) . 3. dermatologic diseases : severe erythema multiforme ( stevens-johnson syndrome ) . severe psoriasis . 4. allergic states : atopic dermatitisserum sickness . 5. ophthalmic diseases : severe acute chronic allergic inflammatory processes involving eye adnexa : allergic conjunctivitis.keratitis . iritis iridocyclitis.diffuse posterior uveitis choroiditis.optic neuritis.chorioretinitis . anterior segment inflammation . 6. respiratory diseases : symptomatic sarcoidosis . 7. edematous states : induce diuresis remission proteinuria nephrotic syndrome without uremia idiopathic type due lupus erythematosus . 8. nervous system : acute exacerbations multiple sclerosis .",
        "doid_entities": [
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "juvenile rheumatoid arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "gouty arthritis (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            },
            {
                "text": "systemic lupus erythematosus (DOID:9074)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9074"
            },
            {
                "text": "lupus (DOID:8857)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8857"
            },
            {
                "text": "dermatomyositis (DOID:10223)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10223"
            },
            {
                "text": "polymyositis (DOID:0080745)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080745"
            },
            {
                "text": "erythema multiforme (DOID:0050185)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050185"
            },
            {
                "text": "stevens-johnson syndrome (DOID:0050426)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050426"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "allergic conjunctivitis (DOID:11204)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11204"
            },
            {
                "text": "conjunctivitis (DOID:6195)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6195"
            },
            {
                "text": "keratitis (DOID:4677)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4677"
            },
            {
                "text": "iritis (DOID:1406)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1406"
            },
            {
                "text": "iridocyclitis (DOID:9383)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9383"
            },
            {
                "text": "posterior uveitis (DOID:12574)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12574"
            },
            {
                "text": "uveitis (DOID:13141)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13141"
            },
            {
                "text": "choroiditis (DOID:11406)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11406"
            },
            {
                "text": "optic neuritis (DOID:1210)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1210"
            },
            {
                "text": "neuritis (DOID:1803)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1803"
            },
            {
                "text": "chorioretinitis (DOID:8886)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8886"
            },
            {
                "text": "sarcoidosis (DOID:11335)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11335"
            },
            {
                "text": "proteinuria (DOID:576)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_576"
            },
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "uremia (DOID:4676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4676"
            },
            {
                "text": "multiple sclerosis (DOID:2377)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2377"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute gouty arthritis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_29207"
            },
            {
                "disease": "acute episode exacerbation",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_35889"
            },
            {
                "disease": "severe erythema multiforme",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_502499"
            },
            {
                "disease": "stevens-johnson syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_36426"
            }
        ]
    },
    "contraindications": {
        "text": "standard tests verification adrenal responsiveness corticotropin may utilize much 80 units single injection one injections lesser . verification tests performed prior treatment corticotropins . test utilize route ( ) proposed treatment . following verification individualized according disease treatment general medical condition patient . frequency dose determined considering severity disease , plasma urine corticosteroid levels initial response patient . gradual change schedules attempted , full effects become apparent . product may administered subcutaneously intramuscularly vial subcutaneously prefilled syringe . treatment acute exacerbations multiple sclerosis daily subcutaneous intramuscular doses 80-120 units 2-3 weeks . chronic 40 units daily may associated uncontrollable effects . reduction indicated accomplished gradually either reducing amount injection , administering injections longer intervals , combination . reduction , careful consideration given disease treated , general medical condition patient duration corticotropin administered . important instructions \u2022parenteral products inspected visually particulate matter discoloration prior whenever solution container permit . purified cortrophin gel clear , light amber liquid gel room temperature . solution discolored cloudy solution contains particulate matter . \u2022purified cortrophin gel solid gel refrigerated needs warmed liquid gel . ofor purified cortrophin gel vials warm rolling hands minutes . ofor purified cortrophin gel prefilled syringes remove carton refrigerator leave room temperature 45 minutes . \u2022the recommended injection sites include abdomen , upper thigh , upper arm . inject within 2 inches navel . information patients advise patients and/or caregivers read fda-approved patient information ( instructions ) .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "multiple sclerosis (DOID:2377)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2377"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic 40 units",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98255"
            }
        ]
    },
    "warningsAndPrecautions": "purified cortrophin gel clear , light amber liquid gel room temperature . supplied sterile : \u2022multiple-dose vials intramuscular subcutaneous package size total volume ndc 1 ml multiple-dose vial 80 usp units/ml 62559-860-11 5 ml multiple-dose vial 400 usp units/5 ml 62559-860-15 \u2022single-dose prefilled syringes subcutaneous package size total volume ndc 0.5 ml single-dose prefilled syringe 40 usp units/0.5 ml 62559-861-35 1 ml single-dose prefilled syringe 80 usp units/ml 62559-861-11",
    "adverseReactions": "purified cortrophin gel contraindicated intravenous . purified cortrophin gel contraindicated patients scleroderma , osteoporosis , systemic fungal infections , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , hypertension , sensitivity proteins derived porcine sources . purified cortrophin gel contraindicated patients primary adrenocortical insufficiency adrenocortical hyperfunction .",
    "indications_original": "Purified Cortrophin Gel is indicated in the following disorders:\n                  1.  Rheumatic disorders: \n                  \n                     \n                        \u00a0As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).Ankylosing spondylitis.Acute gouty arthritis. \n                  \n                  2.  Collagen diseases: \n                  \n                     \n                        \u00a0During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). \n                  \n                  3.  Dermatologic diseases: \n                  \n                     \n                        \u00a0Severe erythema multiforme (Stevens-Johnson syndrome).Severe psoriasis.\n                  \n                  4.  Allergic states: \n                  \n                     \n                        \u00a0Atopic dermatitisSerum sickness. \n                  \n                  5.  Ophthalmic diseases: \n                  \n                     \n                        \u00a0Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:Allergic conjunctivitis.Keratitis. Iritis and iridocyclitis.Diffuse posterior uveitis and choroiditis.Optic neuritis.Chorioretinitis. Anterior segment inflammation. \n                  \n                  6.  Respiratory diseases: \n                  \n                     \n                        \u00a0Symptomatic sarcoidosis. \n                  \n                  7.  Edematous states:\n                  \n                     \n                        \u00a0To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. \n                  \n                  8.  Nervous system:\n                  \n                     \n                        \u00a0Acute exacerbations of multiple sclerosis.",
    "contraindications_original": "Standard tests for verification of adrenal responsiveness to corticotropin may utilize as much as 80 units as a single injection or one or more injections of a lesser dosage. Verification tests should be performed prior to treatment with corticotropins. The test should utilize the route(s) of administration proposed for treatment. Following verification dosage should be individualized according to the disease under treatment and the general medical condition of each patient. Frequency and dose of the drug should be determined by considering severity of the disease, plasma and urine corticosteroid levels and the initial response of the patient. Only gradual change in dosage schedules should be attempted, after full drug effects have become apparent.\n                  This product may be administered subcutaneously or intramuscularly with the vial and subcutaneously with the prefilled syringe.\n                  In the treatment of acute exacerbations of multiple sclerosis daily subcutaneous or intramuscular doses of 80-120 units for 2-3 weeks.\n                  The chronic administration of more than 40 units daily may be associated with uncontrollable adverse effects.\n                  When reduction in dosage is indicated this should be accomplished gradually by either reducing the amount of each injection, or administering injections at longer intervals, or by a combination of both of the above. During reduction of dosage, careful consideration should be given to the disease being treated, the general medical condition of the patient and the duration over which corticotropin was administered.\n                  \n                     Important Administration Instructions\n                  \n                  \n                     \n                        \u2022Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Purified Cortrophin Gel is a clear, light amber liquid gel at room temperature. Do not use if the solution is discolored or cloudy or the solution contains particulate matter.\n                     \n                        \u2022Purified Cortrophin Gel will be a solid gel when refrigerated and needs to be warmed to a liquid gel before administration. \n                           \n                              oFor Purified Cortrophin Gel vials warm by rolling between your hands for a few minutes.\n                           \n                              oFor Purified Cortrophin Gel prefilled syringes remove the carton from the refrigerator and leave at room temperature for 45 minutes.\n                        \n                     \n                     \n                        \u2022The recommended injection sites include abdomen, upper thigh, or upper arm. Do not inject within 2 inches of navel.\n                  \n                  \n                     Information for Patients\n                  \n                  Advise patients and/or caregivers to read the FDA-approved patient information (Instructions for Use).",
    "warningsAndPrecautions_original": "Purified Cortrophin Gel is a clear, light amber liquid gel at room temperature. It is supplied sterile in:\n                  \n                     \n                        \u2022Multiple-dose vials for intramuscular or subcutaneous use\n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Package Size\n                              \n                           \n                           \n                              \n                                 Total Volume\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                        \n                        \n                           \n                              1 mL multiple-dose vial\n                           \n                           \n                              80 USP units/mL\n                           \n                           \n                              62559-860-11\n                           \n                        \n                        \n                           \n                              5 mL multiple-dose vial\n                           \n                           \n                              400 USP units/5 mL\n                           \n                           \n                              62559-860-15\n                           \n                        \n                     \n                  \n                  \n                     \n                        \u2022Single-dose prefilled syringes for subcutaneous use only\n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Package Size\n                              \n                           \n                           \n                              \n                                 Total Volume\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                        \n                        \n                           \n                              0.5 mL single-dose prefilled syringe\n                           \n                           \n                              40 USP units/0.5 mL\n                           \n                           \n                              62559-861-35\n                           \n                        \n                        \n                           \n                              1 mL single-dose prefilled syringe\n                           \n                           \n                              80 USP units/mL\n                           \n                           \n                              62559-861-11",
    "adverseReactions_original": "Purified Cortrophin Gel is contraindicated for intravenous administration. \n                  Purified Cortrophin Gel is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, hypertension, or sensitivity to proteins derived from porcine sources. \n                  Purified Cortrophin Gel is contraindicated in patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.",
    "drug": [
        {
            "name": "Purified Cortrophin Gel",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3892"
        }
    ]
}